Bottom line
PJP vs FTXH: the short answer
PJP (Invesco Pharmaceuticals ETF) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) share a meaningful slice of their top holdings — about 44% by weight.
PJP is cheaper at 0.58% vs 0.6% — a difference of $2.00 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +6.5% for FTXH.
Updated Nov 19, 2026
PJP vs FTXH side by side
| PJP | FTXH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.58% | 0.6% |
| Annual cost per $10k | $58 | $60 |
| 10-yr cost on $10k (prospectus) | $726 | — |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +27.9% | +24.0% |
| 5-yr return (annualized) | +9.0% | +6.5% |
| 10-yr return (annualized) | +5.1% | — |
| Best quarter | +18.1% | +18.3% |
| Worst quarter | −14.8% | −17.4% |
| Net assets (fund) | $472.1M | $36.2M |
| Number of holdings | 33 | 51 |
| Portfolio turnover | 36% | 35% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PJP | FTXH | Difference |
|---|---|---|---|
| 2025 | +27.9% | +24.0% | +3.9% |
| 2024 | +9.7% | +3.0% | +6.8% |
| 2023 | −2.2% | −1.4% | −0.8% |
| 2022 | −2.0% | +2.5% | −4.5% |
| 2021 | +14.5% | +6.1% | +8.4% |
| 2020 | +11.2% | +10.9% | +0.3% |
| 2019 | +4.7% | +22.4% | −17.7% |
| 2018 | −1.7% | −8.4% | +6.7% |
| 2017 | +15.3% | +18.8% | −3.5% |
Source: Fund prospectus bar charts
Holdings overlap
11 of PJP's top 25 holdings also appear in FTXH's top 25.
| Holding | PJP | FTXH |
|---|---|---|
| AbbVie Inc. | 5.48% | 7.39% |
| Amgen Inc. | 5.33% | 3.18% |
| Johnson & Johnson | 5.18% | 6.96% |
| Merck & Co., Inc. | 5.06% | 7.07% |
| Eli Lilly and Co. | 5.02% | 7.77% |
| Gilead Sciences, Inc. | 4.53% | 2.89% |
| Pfizer Inc. | 4.50% | 2.97% |
| Regeneron Pharmaceuticals, Inc. | 3.14% | 2.72% |
| Bristol-Myers Squibb Co. | 2.94% | 6.29% |
| Viatris Inc. | 2.83% | 3.62% |
| Biogen Inc. | 2.75% | 3.84% |
Source: SEC Form N-PORT
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between PJP and FTXH?
Which is cheaper, PJP or FTXH?
Should I own both PJP and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.